AbbVie, SKYRIZI, Risankizumab, RINVOQ, Upadacitinib, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis, Phase 3 AFFIRM, FORTIFY Study, SEQUENCE Study, COMMAND Study

North Chicago, Illinois, USA, October 11, 2026 AbbVie has announced new clinical and real-world evidence supporting SKYRIZI® (risankizumab-rzaa) and...